Peer-Reviewed Evidence for AI Stroke Detection in ERs

For hospitals evaluating AI tools for early stroke detection in emergency rooms, the useful question is not whether an algorithm can flag a suspicious CT angiogram. The question is whether that alert changes the part of the acute stroke pathway that is actually delaying care: image acquisition, interpretation, neurologist notification, transfer acceptance, thrombectomy team activation, or groin puncture.

Viz.ai, RapidAI, and Brainomix all sit in a more mature category than research prototypes. They have FDA-cleared stroke imaging products, peer-reviewed or trial-adjacent evidence, and real deployment in acute stroke workflows. The evidence is strongest for diagnostic support and workflow acceleration. It is weaker, and in some places still absent, for the endpoint patients and stroke teams ultimately care about: functional independence at 90 days.

What the Evidence Shows at a Glance

The table is deliberately asymmetrical because the literature is asymmetrical. A cluster randomized trial, a vendor product page citing performance and trial participation, and a very large observational deployment study do not answer the same question. Treating them as interchangeable would make the comparison cleaner and less useful.

Viz.ai: the Clearest Randomized Workflow Signal

Viz.ai matters historically because it helped define the FDA category. In 2018, the FDA permitted marketing of clinical decision support software intended to analyze CT angiography images and notify a neurovascular specialist when findings suggested a potential large vessel occlusion [1]. That clearance established a regulatory lane for computer-aided stroke triage. It did not, by itself, prove that patients reached thrombectomy faster or left the hospital less disabled.

The more decision-relevant evidence is the JAMA Neurology cluster randomized clinical trial. In the summarized data available through the reviewed literature, automated LVO detection and notification was associated with a reduction in door-to-groin puncture time from 100 minutes to 88 minutes [2]. That is the kind of endpoint a stroke operations group can map onto its own process: the patient has already arrived, imaging has occurred, and the system is trying to compress the interval between recognition and arterial access.

A 12-minute reduction is not a miracle claim. It is also not trivial. In an LVO workflow, 12 minutes can represent fewer phone calls, less uncertainty about who has seen the scan, or earlier alignment between the ED, radiology, neurology, and interventional team. The platform’s cited diagnostic evidence also includes 97% specificity for LVO detection in a 3,851-patient study, a figure that matters because false-positive alerts create work for exactly the clinicians who are already operating under time pressure [2].

The limitation is equally important. The trial supports a workflow effect, not a completed outcomes argument. It does not establish that Viz.ai improves 90-day modified Rankin Scale outcomes in a prospective trial. For a hospital committee, that means the adoption case can be credible without being overstated: faster thrombectomy workflow is supported; functional independence improvement remains unproven.

RapidAI: Broad Imaging Coverage, but Different Evidence Types

RapidAI is difficult to evaluate as a single “stroke detection tool” because the product family spans much more than one binary alert. The company describes modules including NCCT Stroke, ASPECTS, LMVO, CTA, perfusion, and AngioFlow, which places the platform across initial CT review, vessel assessment, tissue selection, and angiographic workflow [3]. That breadth is attractive in a comprehensive stroke program, but it also makes evidence interpretation harder: a metric for LVO sensitivity is not evidence for every module in the suite.

The most concrete diagnostic figure in the cited material is RAPID LVO sensitivity of 96% in a 760-patient study [3]. Sensitivity is especially relevant for LVO triage because a missed occlusion can mean a missed transfer or delayed thrombectomy evaluation. But sensitivity alone does not tell the whole ED story. Specificity, alert burden, image quality failures, posterior circulation performance, and local transfer rules all influence whether the alert improves care or simply adds another notification.

RapidAI also has a distinctive role in the thrombectomy evidence ecosystem because RAPID imaging technology was used in major thrombectomy trial workflows, including DAWN, DEFUSE 3, and SWIFT-PRIME [3]. That history is meaningful. It shows that RAPID-derived imaging outputs have been embedded in high-stakes selection workflows. It should not be casually converted into proof that purchasing the current platform will independently improve outcomes in a given emergency department.

The same caution applies to adoption claims. Vendor-disclosed statements about market penetration or use at comprehensive stroke centers may help explain why a platform is familiar to stroke teams, but they are not independent evidence of clinical effectiveness. For procurement purposes, RapidAI’s strongest case is its breadth and its connection to established imaging-selection workflows; its weakest point, in this evidence set, is the lack of a direct prospective outcomes trial attributable to the platform itself.

Brainomix: Large-Scale Deployment Evidence That Still Needs Careful Reading

Brainomix deserves attention because the scale of the cited evidence is unusual for this field. The company describes Brainomix 360 Stroke as supported by a Lancet Digital Health 2025 study involving more than 450,000 patients, and the same evidence base is discussed in a 2025 systematic review of AI stroke imaging tools [4][5]. In a field often dominated by single-center retrospective accuracy studies, that scale changes the conversation.

The headline figures are also striking: the evidence cited through Brainomix and the systematic review reports an association with a 100% increase in mechanical thrombectomy rates and, at a primary stroke center, functional independence improving from 16% to 48% [4][5]. Those numbers are clinically hard to ignore. They speak to a plausible system effect: if more eligible patients are identified, transferred, and treated, thrombectomy rates can rise.

But the word “associated” has to stay visible. A large observational or implementation evidence base can show that outcomes changed after deployment or in sites using the tool. It cannot automatically isolate the algorithm from parallel changes in staffing, transfer pathways, training, thrombectomy capacity, or regional stroke network behavior. The reported functional independence improvement is therefore a signal worth studying, not the same thing as a prospective randomized proof that Brainomix caused better 90-day mRS outcomes.

For hospitals, Brainomix may be most compelling where the problem is not only detection but network coordination: primary stroke centers, transfer decisions, and variability in early ischemic change interpretation. The large evidence base makes it a serious contender. It does not make it directly rankable above Viz.ai or RapidAI, because the underlying study designs and endpoints are not matched.

Why ASPECTS Automation Matters Across Platforms

Automated ASPECTS scoring is sometimes treated as a secondary feature next to LVO detection, but in practice it can be central to whether teams agree on what the scan means. ASPECTS is a structured way to estimate early ischemic change on noncontrast CT. Under emergency conditions, reader variability is not a theoretical problem; it affects confidence, eligibility discussions, and transfer urgency.

The cited Radiology 2019 evidence is useful because it focuses on agreement rather than marketing convenience. Automated ASPECTS systems achieved inter-reader agreement up to κ=0.90, compared with κ=0.56–0.57 for individual neuroradiologists, with the effect most pronounced in the hyperacute 1- to 4-hour window [6]. That does not mean the software is always right. It means automation may reduce one source of variability at exactly the point where stroke teams are making fast treatment decisions from imperfect images.

This is also where platform comparisons can become misleading. If one hospital is struggling with delayed LVO notification, the most relevant evidence may be alert speed and specificity. If another is struggling with inconsistent early ischemic change reads before transfer, ASPECTS agreement may matter more. A single leaderboard cannot capture those different operational failures.

What Still Has Not Been Shown

The current literature supports a disciplined but favorable interpretation: AI stroke imaging tools can improve diagnostic support and can shorten parts of the treatment pathway. A 2025 systematic review of 31 studies concluded that AI stroke imaging tools have consistently shown improved diagnostic accuracy metrics, while the link to functional outcomes remains unproven [5]. That is the boundary.

• No direct head-to-head trial shows that Viz.ai, RapidAI, or Brainomix is superior overall.
• No platform has demonstrated improved 90-day modified Rankin Scale functional independence in a prospective trial.
• Study designs differ enough that sensitivity, specificity, time-to-treatment, thrombectomy rate, and functional independence associations should not be collapsed into one score.
• Cost-effectiveness and return-on-investment evidence remains thin in the cited literature.
• Posterior circulation stroke and special populations remain evidence gaps across the platform category.

This is why FDA clearance should be read as a regulatory threshold, not an outcomes guarantee. Diagnostic accuracy should be read against the target condition and reference standard. Faster alerts should be traced to the exact workflow step that changed. A hospital does not buy an mRS improvement; it buys a triage and coordination intervention that may or may not translate into downstream benefit in its own system.

For a fuller discussion of why workflow gains have not yet closed the outcomes question, the natural continuation is ClinicalMind’s analysis of AI stroke workflow versus outcomes. The short version for adoption decisions is simpler: these tools are mature enough to evaluate seriously, especially for LVO triage, ASPECTS consistency, and time-sensitive coordination. They are not mature enough to treat clearance, adoption, or non-comparable study metrics as proof that one platform delivers better long-term patient outcomes than the others.

References

1. FDA permits marketing of clinical decision support software for alerting providers of a potential stroke, U.S. Food and Drug Administration, 2018
2. Automated Large Vessel Occlusion Detection Software and Thrombectomy Treatment Times: A Cluster Randomized Clinical Trial, JAMA Neurology, 2023
3. Ischemic Stroke, RapidAI
4. Brainomix 360 Stroke, Brainomix
5. Artificial intelligence in stroke imaging: systematic review, PMC, 2025
6. Automated Calculation of the Alberta Stroke Program Early CT Score: Feasibility and Reliability, Radiology, 2019